Alvotech (ALVO) Stock Forecast, Price Target & Predictions
ALVO Stock Forecast
Alvotech stock forecast is as follows: an average price target of $16.00 (represents a 45.32% upside from ALVO’s last price of $11.01) and a rating consensus of 'Hold', based on 3 wall street analysts offering a 1-year stock forecast.
ALVO Price Target
The average price target for Alvotech (ALVO) is $16.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $22.00 to $10.00. This represents a potential 45.32% upside from ALVO's last price of $11.01.
ALVO Analyst Ratings
According to 3 Wall Street analysts, Alvotech's rating consensus is 'Hold'. The analyst rating breakdown for ALVO stock is 0 'Strong Buy' (0.00%), 1 'Buy' (33.33%), 2 'Hold' (66.67%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Alvotech Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 24, 2024 | Balaji Prasad | Barclays | $22.00 | $13.58 | 62.00% | 99.82% |
| May 21, 2024 | Balaji Prasad | Barclays | $20.00 | $13.76 | 45.35% | 81.65% |
| Jan 29, 2024 | Balaji Prasad | Barclays | $17.00 | $15.25 | 11.48% | 54.41% |
| Jul 01, 2022 | Emmanuel Papadakis | Deutsche Bank | $10.00 | $8.21 | 21.80% | -9.17% |
The latest Alvotech stock forecast, released on May 24, 2024 by Balaji Prasad from Barclays, set a price target of $22.00, which represents a 62.00% increase from the stock price at the time of the forecast ($13.58), and a 99.82% increase from ALVO last price ($11.01).
Alvotech Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 3 |
| Avg Price Target | - | - | $19.67 |
| Last Closing Price | $11.01 | $11.01 | $11.01 |
| Upside/Downside | -100.00% | -100.00% | 78.66% |
In the current month, the average price target of Alvotech stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Alvotech's last price of $11.01. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| May 21, 2024 | Barclays | Overweight | Overweight | Hold |
| Jan 29, 2024 | Barclays | - | Overweight | Upgrade |
| Oct 20, 2023 | Citigroup | - | Neutral | Upgrade |
| Jul 01, 2022 | Deutsche Bank | - | Hold | Initialise |
Alvotech's last stock rating was published by Barclays on May 21, 2024. The company gave ALVO a "Overweight" rating, the same as its previous rate.
Alvotech Financial Forecast
Alvotech Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $89.86M | $82.41M | $75.59M | $69.32M | $115.50M | $113.50M | $53.48M | $12.43M | $93.00M | $34.94M | $42.00M |
| High Forecast | $93.90M | $86.12M | $78.98M | $72.44M | $120.69M | $119.05M | $55.89M | $12.43M | $97.18M | $34.94M | $43.89M |
| Low Forecast | $85.82M | $78.71M | $72.19M | $66.21M | $110.31M | $107.94M | $51.08M | $12.43M | $88.82M | $34.94M | $40.11M |
| # Analysts | - | - | - | - | 1 | 2 | 1 | - | 1 | 1 | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Alvotech's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. ALVO's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Alvotech EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 2 | 1 | - | 1 | 1 | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $-89.86M | $-82.41M | $-75.59M | $-69.32M | $-115.50M | $-113.50M | $-53.48M | $-12.43M | $-93.00M | $-34.94M | $-42.00M |
| High Forecast | $-85.82M | $-78.71M | $-72.19M | $-66.21M | $-110.31M | $-107.94M | $-51.08M | $-12.43M | $-88.82M | $-34.94M | $-40.11M |
| Low Forecast | $-93.90M | $-86.12M | $-78.98M | $-72.44M | $-120.69M | $-119.05M | $-55.89M | $-12.43M | $-97.18M | $-34.94M | $-43.89M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
undefined analysts predict ALVO's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Alvotech's previous annual EBITDA (undefined) of $NaN.
Alvotech Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 2 | 1 | - | 1 | 1 | - |
| Net Income | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $25.15M | $30.73M | $13.97M | $13.97M | $2.79M | $-47.50M | $838.22K | $-22.15M | $11.74M | $-18.68M | $-39.12M |
| High Forecast | $26.62M | $32.53M | $14.79M | $14.79M | $2.96M | $-44.72M | $887.20K | $-22.15M | $12.42M | $-18.68M | $-36.83M |
| Low Forecast | $23.68M | $28.94M | $13.15M | $13.15M | $2.63M | $-50.27M | $789.25K | $-22.15M | $11.05M | $-18.68M | $-41.40M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Alvotech's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ALVO's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Alvotech SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 2 | 1 | - | 1 | 1 | - |
| SG&A | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $139.83M | $128.24M | $117.62M | $107.87M | $179.73M | $176.61M | $83.22M | $19.34M | $144.72M | $54.37M | $65.36M |
| High Forecast | $146.11M | $134.01M | $122.90M | $112.72M | $187.80M | $185.25M | $86.96M | $19.34M | $151.22M | $54.37M | $68.29M |
| Low Forecast | $133.54M | $122.48M | $112.33M | $103.03M | $171.65M | $167.96M | $79.48M | $19.34M | $138.21M | $54.37M | $62.42M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Alvotech's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to ALVO last annual SG&A of $NaN (undefined).
Alvotech EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 2 | 1 | - | 1 | 1 | - |
| EPS | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $0.09 | $0.11 | $0.05 | $0.05 | $0.01 | $-0.17 | - | $-0.08 | $0.04 | $-0.07 | $-0.14 |
| High Forecast | $0.10 | $0.12 | $0.05 | $0.05 | $0.01 | $-0.16 | - | $-0.08 | $0.04 | $-0.07 | $-0.13 |
| Low Forecast | $0.08 | $0.10 | $0.05 | $0.05 | $0.01 | $-0.18 | - | $-0.08 | $0.04 | $-0.07 | $-0.15 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Alvotech's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ALVO previous annual EPS of $NaN (undefined).
Alvotech Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PCRX | Pacira BioSciences | $14.35 | $43.00 | 199.65% | Hold |
| ASRT | Assertio | $1.30 | $2.88 | 121.54% | Buy |
| LFCR | Lifecore Biomedical | $5.08 | $8.00 | 57.48% | Buy |
| CYTH | Cyclo Therapeutics | $0.65 | $0.95 | 46.15% | Buy |
| ALVO | Alvotech | $11.01 | $16.00 | 45.32% | Hold |
| AMPH | Amphastar Pharmaceuticals | $48.64 | $66.00 | 35.69% | Buy |
| ALKS | Alkermes | $27.74 | $35.50 | 27.97% | Buy |
| ITCI | Intra-Cellular Therapies | $75.11 | $94.00 | 25.15% | Buy |
| CTLT | Catalent | $60.35 | $74.30 | 23.12% | Hold |
| ANIP | ANI Pharmaceuticals | $60.06 | $67.33 | 12.10% | Buy |
| COLL | Collegium Pharmaceutical | $37.38 | $41.50 | 11.02% | Buy |
ALVO Forecast FAQ
Is Alvotech a good buy?
No, according to 3 Wall Street analysts, Alvotech (ALVO) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 33.33% of ALVO's total ratings.
What is ALVO's price target?
Alvotech (ALVO) average price target is $16 with a range of $10 to $22, implying a 45.32% from its last price of $11.01. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Alvotech stock go up soon?
According to Wall Street analysts' prediction for ALVO stock, the company can go up by 45.32% (from the last price of $11.01 to the average price target of $16), up by 99.82% based on the highest stock price target, and down by -9.17% based on the lowest stock price target.
Can Alvotech stock reach $20?
ALVO's highest twelve months analyst stock price target of $22 supports the claim that Alvotech can reach $20 in the near future.
What are Alvotech's analysts' financial forecasts?
Alvotech's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $294.91M (high $308.06M, low $281.76M), average EBITDA is $-295M (high $-282M, low $-308M), average net income is $-66.013M (high $-63.027M, low $-69M), average SG&A $458.91M (high $479.36M, low $438.43M), and average EPS is $-0.24 (high $-0.229, low $-0.251). ALVO's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $317.18M (high $331.44M, low $302.93M), average EBITDA is $-317M (high $-303M, low $-331M), average net income is $83.82M (high $88.72M, low $78.92M), average SG&A $493.56M (high $515.75M, low $471.38M), and average EPS is $0.3 (high $0.318, low $0.282).